

HitGen, Ammirall to identify novel drug targets

26 March 2019 | News

HitGen will receive upfront payments, and be eligible for milestone payments from Ammirall



HitGen has announced that the company has entered into a research collaboration with Ammirall to identify novel small molecule leads for targets of interest.

In this collaboration, HitGen will apply its technology platform, based on DNA-encoded library design, synthesis and screening, to discover novel leads for Ammirall.

Dr Jin Li, Chairman of the Board and Chief Executive Officer of HitGen said, "We are delighted to enter this collaboration with Ammirall, a leading medical dermatology focused global pharmaceutical company. This collaboration further reemphasizes the role of HitGen in the rapidly developing field of DNA-encoded chemistry. We will work closely with Ammirall scientists to generate novel leads for their innovative research programs to address unmet medical needs."

Dr Bhushan Hardas, Chief Scientific Officer of Ammirall, commented, "Agreement keeps us on the track to achieve our goal of becoming a leading medical dermatology company. We look forward to collaborate with HitGen in identifying new molecules with the potential of becoming new treatment options for patients with atopic dermatitis."

Under the terms of the agreement, HitGen will receive upfront payments, and be eligible for milestone payments from Ammirall. Specific financial details were not disclosed.